{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T22:09:35Z","timestamp":1785190175835,"version":"3.55.0"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T00:00:00Z","timestamp":1271116800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1038\/nrneph.2010.37","type":"journal-article","created":{"date-parts":[[2010,4,13]],"date-time":"2010-04-13T09:58:53Z","timestamp":1271152733000},"page":"395-403","source":"Crossref","is-referenced-by-count":34,"title":["Hepatic disorders in chronic kidney disease"],"prefix":"10.1038","volume":"6","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,4,13]]},"reference":[{"key":"BFnrneph201037_CR1","unstructured":"Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Hepatitis C in chronic kidney disease. Kidney Int. 73 (Suppl. 109), S1\u2013S99 (2008)."},{"key":"BFnrneph201037_CR2","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/ndt\/12.7.1394","volume":"12","author":"F Fabrizi","year":"1997","unstructured":"Fabrizi, F. et al. Influence of hepatitis C virus (HCV) viraemia upon serum aminotransferase activity in chronic dialysis patients. Nephrol. Dial. Transplant. 12, 1394\u20131398 (1997).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/S0272-6386(87)80071-9","volume":"6","author":"J Josselson","year":"1987","unstructured":"Josselson, J., Kyser, B. A., Weir, M. R. & Sadler, J. H. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am. J. Kidney Dis. 6, 456\u2013461 (1987).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201037_CR4","first-page":"98","volume":"6","author":"R Jha","year":"1993","unstructured":"Jha, R. et al. Hepatitis B associated liver disease in dialysis patients: role of vaccination. J. Nephrol. 6, 98\u2013103 (1993).","journal-title":"J. Nephrol."},{"key":"BFnrneph201037_CR5","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1177\/039139880302601202","volume":"26","author":"F Fabrizi","year":"2003","unstructured":"Fabrizi, F. et al. Influence of hepatitis B virus viremia upon serum aminotransferase activity in dialysis population. Int. J. Artif. Organs 26, 1048\u20131055 (2003).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/039139880703000103","volume":"30","author":"F Fabrizi","year":"2007","unstructured":"Fabrizi, F. et al. Gamma-glutamyltranspeptidase activity and viral hepatitis in dialysis population. Int. J. Artif. Organs 30, 6\u201315 (2007).","journal-title":"Int. J. Artif. Organs"},{"issue":"Suppl. 1","key":"BFnrneph201037_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1055\/s-2004-828680","volume":"24","author":"F Fabrizi","year":"2004","unstructured":"Fabrizi, F., Bunnapradist, S. & Martin, P. HBV infection in patients with end-stage renal disease. Semin. Liver Dis. 24 (Suppl. 1), 63\u201370 (2004).","journal-title":"Semin. Liver Dis."},{"key":"BFnrneph201037_CR8","first-page":"2153","volume":"19","author":"E Rivolta","year":"1987","unstructured":"Rivolta, E. et al. Prognostic significance of hepatitis B surface antigenemia in cadaveric renal transplant patients. Transplant. Proc. 19, 2153\u20132154 (1987).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/00007890-199003000-00013","volume":"49","author":"CC Huang","year":"1990","unstructured":"Huang, C. C., Lai, M. K. & Fong, M. T. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 49, 540\u2013544 (1990).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR10","first-page":"2155","volume":"19","author":"GL Flagg","year":"1987","unstructured":"Flagg, G. L., Silberman, H., Takamoto, S. K. & Berne, T. V. The influence of hepatitis B infection on the outcome of renal allotransplantation. Transplant. Proc. 19, 2155\u20132158 (1987).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/hep.510290123","volume":"29","author":"P Mathurin","year":"1999","unstructured":"Mathurin, P. et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29, 257\u2013263 (1999).","journal-title":"Hepatology"},{"key":"BFnrneph201037_CR12","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1097\/01.TP.0000161250.83392.73","volume":"79","author":"A Aroldi","year":"2005","unstructured":"Aroldi, A. et al. Natural history of hepatitis B and C in renal allograft recipients. Transplantation 79, 1132\u20131136 (2005).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1399-0012.1992.tb00861.x","volume":"46","author":"C Hiesse","year":"1992","unstructured":"Hiesse, C. et al. Impact of HBs antigenemia on long-term patient survival and causes of death after renal transplantation. Clin. Transplant. 46, 461\u2013467 (1992).","journal-title":"Clin. Transplant."},{"key":"BFnrneph201037_CR14","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1002\/jmv.20980","volume":"79","author":"HJ Ahn","year":"2007","unstructured":"Ahn, H. J. et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J. Med. Virol. 79, 1655\u20131663 (2007).","journal-title":"J. Med. Virol."},{"key":"BFnrneph201037_CR15","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1111\/j.1600-6143.2005.01113.x","volume":"5","author":"F Fabrizi","year":"2005","unstructured":"Fabrizi, F., Martin, P., Dixit, V., Kanwal, F. & Dulai, G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 5, 2913\u20132921 (2005).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR16","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1097\/00007890-198112000-00011","volume":"32","author":"MP LaQuaglia","year":"1981","unstructured":"LaQuaglia, M. P. et al. Impact of hepatitis on renal transplantation. Transplantation 32, 504\u2013507 (1981).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR17","first-page":"1490","volume":"28","author":"JB Chen","year":"1996","unstructured":"Chen, J. B., Hsieh, H., Hsu, K. T. & Chen, C. H. Impact of donor hepatitis B antigenemia on renal allograft in hepatitis B recipients. Transplant. Proc. 28, 1490\u20131492 (1996).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR18","first-page":"161","volume":"54","author":"H Taskapan","year":"2000","unstructured":"Taskapan, H., Oymak, O., Dogukan, A., Ozbakir, O. & Utas, C. Transformation of hepatitis B virus-related membranoproliferative glomerulonephritis to crescentic form. Clin. Nephrol. 54, 161\u2013163 (2000).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201037_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1073\/pnas.84.5.1187","volume":"84","author":"H Farza","year":"1987","unstructured":"Farza, H. et al. Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice. Proc. Natl Acad. Sci. USA 84, 1187\u20131191 (1987).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrneph201037_CR20","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hep.1840220107","volume":"22","author":"JS McMillan","year":"1995","unstructured":"McMillan, J. S., Shaw, T., Angus, P. W. & Locarnini, S. A. Effect of immunosuppressive and antiviral agents on hepatitis B virus replication in vitro. Hepatology 22, 36\u201343 (1995).","journal-title":"in vitro. Hepatology"},{"key":"BFnrneph201037_CR21","volume-title":"International Symposium on Viral Hepatitis and Liver Disease","author":"PJ Cote","year":"1990","unstructured":"Cote, P. J., Tennant, B. C., Baldwin, B., Korba, B. E. & Gerin, J. L. Modulation of WHV infection and disease with cyclosporine A and dexamethasone. International Symposium on Viral Hepatitis and Liver Disease (Houston, 1990)."},{"key":"BFnrneph201037_CR22","first-page":"385","volume":"49","author":"W Grotz","year":"1998","unstructured":"Grotz, W. et al. Occurrence and management of hepatitis B virus reactivation following kidney transplantation. Clin. Nephrol 49, 385\u2013388 (1998).","journal-title":"Clin. Nephrol"},{"key":"BFnrneph201037_CR23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1365-2893.2007.00868.x","volume":"14","author":"F Fabrizi","year":"2007","unstructured":"Fabrizi, F. et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J. Viral Hepat. 14, 697\u2013703 (2007).","journal-title":"J. Viral Hepat."},{"key":"BFnrneph201037_CR24","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1681\/ASN.2006070736","volume":"18","author":"K Kalantar-Zadeh","year":"2007","unstructured":"Kalantar-Zadeh, K. et al. Hepatitis C virus and death risk in hemodialysis patients. J. Am. Soc. Nephrol. 18, 1584\u20131593 (2007).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201037_CR25","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1093\/ndt\/gfn684","volume":"24","author":"DW Johnson","year":"2009","unstructured":"Johnson, D. W. et al. Frequencies of hepatitis B and C infections among haemodialysis and peritoneal dialysis patients in Asia-Pacific countries: analysis of registry data. Nephrol. Dial. Transplant. 24, 1598\u20131603 (2009).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR26","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1177\/039139880903200801","volume":"32","author":"F Fabrizi","year":"2009","unstructured":"Fabrizi, F., Messa, P & Martin, P. Health-related quality of life in dialysis patients with HCV infection. Int. J. Artif. Organs 32, 473\u2013481 (2009).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.1542-4758.2009.00329.x","volume":"13","author":"B Afsar","year":"2009","unstructured":"Afsar, B., Ozdemir, N. F., Sezer, S. & Haberal, M. Quality of life is not related with liver disease severity but with anemia, malnutrition, and depression in HCV-infected hemodialysis patients. Hemodial. Int. 13, 62\u201371 (2009).","journal-title":"Hemodial. Int."},{"key":"BFnrneph201037_CR28","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s11255-009-9576-3","volume":"41","author":"B Afsar","year":"2009","unstructured":"Afsar, B., Elsurer, R., Sezer, S. & Ozdemir, N. F. Quality of life in hemodialysis patients: hepatitis C virus makes sense. Int. Urol. Nephrol. 41, 1011\u20131019 (2009).","journal-title":"Int. Urol. Nephrol."},{"key":"BFnrneph201037_CR29","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.3748\/wjg.v10.i15.2209","volume":"10","author":"K Okuda","year":"2004","unstructured":"Okuda, K. & Yokosuka, O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4\u201323 years of follow-up. World J. Gastroenterol. 10, 2209\u20132212 (2004).","journal-title":"World J. Gastroenterol."},{"key":"BFnrneph201037_CR30","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/j.1600-6143.2005.00864.x","volume":"5","author":"F Fabrizi","year":"2005","unstructured":"Fabrizi, F., Martin, P., Dixit, V., Bunnapradist, S. & Dulai, G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am. J. Transplant. 5, 1452\u20131461 (2005).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR31","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/j.1399-0012.2004.00256.x","volume":"18","author":"L Wolffenb\u00fcttel","year":"2004","unstructured":"Wolffenb\u00fcttel, L., Poli, D. D., Manfro, R. C. & Goncalves, L. F. Cyclosporine pharmacokinetics in anti-HCV positive patients. Clin. Transplant. 18, 654\u2013680 (2004).","journal-title":"Clin. Transplant."},{"key":"BFnrneph201037_CR32","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1097\/00007890-199812270-00021","volume":"66","author":"MK Ali","year":"1998","unstructured":"Ali, M. K. et al. Donor hepatitis C virus status does not adversely affect short-term outcomes in HCV positive recipients in renal transplantation. Transplantation 66, 1694\u20131697 (1998).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR33","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1034\/j.1399-0012.2000.14040602.x","volume":"14","author":"AK Mandal","year":"2000","unstructured":"Mandal, A. K. et al. Shorter waiting times for hepatitis C virus seropositive recipients of cadaveric renal allografts from hepatitis C virus seropositive donors. Clin. Transplant. 14, 391\u2013396 (2000).","journal-title":"Clin. Transplant."},{"key":"BFnrneph201037_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/ki.1995.29","volume":"47","author":"JM Morales","year":"1995","unstructured":"Morales, J. M. et al. Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV. Kidney Int. 47, 236\u2013240 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph201037_CR35","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1034\/j.1399-0012.2003.00067.x","volume":"17","author":"KJ Woodside","year":"2003","unstructured":"Woodside, K. J. et al. Use of kidneys from hepatitis C seropositive donors shortens waitlist time but does not alter one-year outcome. Clin. Transplant. 17, 433\u2013437 (2003).","journal-title":"Clin. Transplant."},{"key":"BFnrneph201037_CR36","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1097\/01.ASN.0000034944.90425.75","volume":"13","author":"JR Bucci","year":"2002","unstructured":"Bucci, J. R. et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J. Am. Soc. Nephrol. 13, 2974\u20132982 (2002).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201037_CR37","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1097\/01.ASN.0000090743.43034.72","volume":"14","author":"KC Abbott","year":"2003","unstructured":"Abbott, K. C. et al. Hepatitis C and renal transplantation in the era of modern immunosuppression. J. Am. Soc. Nephrol. 14, 2908\u20132918 (2003).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201037_CR38","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1046\/j.1600-6143.2004.00606.x","volume":"4","author":"KC Abbott","year":"2004","unstructured":"Abbott, K. C. et al. The impact of transplantation with deceased donor hepatitis C-positive kidneys on survival in wait-listed long-term dialysis patients. Am. J. Transplant. 4, 2032\u20132037 (2004).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR39","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1097\/01.ASN.0000145439.48387.BF","volume":"15","author":"KC Abbott","year":"2004","unstructured":"Abbott, K. C. et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. J. Am. Soc. Nephrol. 15, 3166\u20133174 (2004).","journal-title":"J. Am. Soc. Nephrol."},{"key":"BFnrneph201037_CR40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1097\/00007890-199510150-00004","volume":"60","author":"A Widell","year":"1995","unstructured":"Widell, A. et al. Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60, 642\u2013647 (1995).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR41","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1600-6143.2004.00504.x","volume":"4","author":"T Schussler","year":"2004","unstructured":"Schussler, T., Staffeld-Coit, C., Eason, J. & Nair, S. Severe hepatitis C infection in a renal transplant recipient following hepatitis C genotype mismatch transplant. Am. J. Transplant. 4, 1375\u20131378 (2004).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR42","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1046\/j.1523-1755.1999.00594.x","volume":"56","author":"SN Natov","year":"1999","unstructured":"Natov, S. N. et al. Hepatitis C virus genotype does not affect patient survival among renal transplant candidates. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 56, 700\u2013706 (1999).","journal-title":"Kidney Int."},{"key":"BFnrneph201037_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S0140-6736(94)91224-6","volume":"343","author":"ME Lai","year":"1994","unstructured":"Lai, M. E. et al. Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343, 388\u2013390 (1994).","journal-title":"Lancet"},{"key":"BFnrneph201037_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.dld.2006.12.017","volume":"39","author":"A Marzano","year":"2007","unstructured":"Marzano, A. et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig. Liver Dis. 39, 397\u2013408 (2007).","journal-title":"Dig. Liver Dis."},{"key":"BFnrneph201037_CR45","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1111\/j.1572-0241.2000.03296.x","volume":"95","author":"Z Ben-Ari","year":"2000","unstructured":"Ben-Ari, Z., Broida, E., Kittai, Y., Chagnac, A. & Tur-Kaspa, R. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am. J. Gastroenterol. 95, 3579\u20133583 (2000).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrneph201037_CR46","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1016\/S0041-1345(02)02879-8","volume":"34","author":"S Boyacioglu","year":"2002","unstructured":"Boyacioglu, S., G\u00fcr, G., G\u00fcrsoy, M. & Ozdemir, N. Lamivudine in renal transplant candidates with chronic hepatitis B infection. Transplant. Proc. 34, 2131\u20132132 (2002).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR47","doi-asserted-by":"publisher","first-page":"400","DOI":"10.3748\/wjg.v11.i3.400","volume":"11","author":"TW Lapinski","year":"2005","unstructured":"Lapinski, T. W., Flisiak, R., Jaroszewicz, J., Michalewicz, M. & Kowalczuc, O. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J. Gastroenterol. 11, 400\u2013402 (2005).","journal-title":"World J. Gastroenterol."},{"key":"BFnrneph201037_CR48","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/00004836-200307000-00016","volume":"37","author":"H Schmilovitz-Weiss","year":"2003","unstructured":"Schmilovitz-Weiss, H., Melzer, E., Tur-Kaspa, R. & Ben-Ari, Z. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J. Clin. Gastroenterol. 37, 64\u201367 (2003).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFnrneph201037_CR49","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1097\/00007890-200005270-00020","volume":"69","author":"H Fontaine","year":"2000","unstructured":"Fontaine, H. et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 69, 2090\u20132094 (2000).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR50","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1177\/039139880803100503","volume":"31","author":"F Fabrizi","year":"2008","unstructured":"Fabrizi, F., Marzano, A., Martin, P. & Lampertico, P. Hepatitis B virus infection in the dialysis population: current perspectives. Int. J. Artif. Organs 31, 386\u2013394 (2008).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR51","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1097\/01.TP.0000116448.97841.6D","volume":"77","author":"F Fabrizi","year":"2004","unstructured":"Fabrizi, F., Dulai, G., Dixit, V., Bunnapradist, S. & Martin, P. Lamivudine for the treatment of hepatitis B virus-related liver disease after renal transplantation: meta-analysis of clinical trials. Transplantation 77, 859\u2013864 (2004).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR52","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1177\/039139880703000405","volume":"30","author":"M Zubkin","year":"2007","unstructured":"Zubkin, M. et al. Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Int. J. Artif. Organs 30, 308\u2013314 (2007).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/135965350501000611","volume":"10","author":"M Vigan\u00f2","year":"2005","unstructured":"Vigan\u00f2, M. et al. Long-term lamivudine monotherapy in renal transplant recipients with hepatitis B-related cirrhosis. Antivir. Ther. 10, 709\u2013713 (2005).","journal-title":"Antivir. Ther."},{"key":"BFnrneph201037_CR54","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jcv.2004.07.001","volume":"31","author":"N Kamar","year":"2004","unstructured":"Kamar, N. et al. Effects of long-term lamivudine therapy in renal-transplant patients. J. Clin. Virol. 31, 298\u2013303 (2004).","journal-title":"J. Clin. Virol."},{"key":"BFnrneph201037_CR55","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1097\/00042737-200412000-00022","volume":"16","author":"D Thabut","year":"2004","unstructured":"Thabut, D. et al. Long-term therapy with lamivudine in renal transplant recipients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 16, 1367\u20131373 (2004).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"BFnrneph201037_CR56","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/j.1478-3231.2005.01171.x","volume":"25","author":"HJ de Silva","year":"2005","unstructured":"de Silva, H. J., Herath, C. A. & Sheriff, M. H. Lamivudine therapy for hepatitis B infection in post-renal transplant patients: results after 36 months follow-up. Liver Int. 25, 1074\u20131075 (2005).","journal-title":"Liver Int."},{"key":"BFnrneph201037_CR57","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1053\/jhep.2002.36156","volume":"36","author":"TM Chan","year":"2002","unstructured":"Chan, T. M. et al. Preemptive lamivudine therapy based on HBV DNA level in HBsAg positive kidney allograft recipients. Hepatology 36, 1246\u20131252 (2002).","journal-title":"Hepatology"},{"key":"BFnrneph201037_CR58","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1097\/01.tp.0000178305.39231.a2","volume":"80","author":"H Fontaine","year":"2005","unstructured":"Fontaine, H. et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 80, 1086\u20131092 (2005).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR59","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1016\/j.transproceed.2006.08.186","volume":"38","author":"HJ de Silva","year":"2006","unstructured":"de Silva, H. J., Dassanayake, A. S., Manamperi, A. & de Silva, A. P. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant. Proc. 38, 3118\u20133120 (2006).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.5414\/CNP71036","volume":"71","author":"N Kamar","year":"2009","unstructured":"Kamar, N. et al. Renal side effects of adefovir in hepatitis B virus positive kidney allograft recipients. Clin. Nephrol. 71, 36\u201342 (2009).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201037_CR61","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1097\/TP.0b013e3181806c8c","volume":"86","author":"N Kamar","year":"2008","unstructured":"Kamar, N. et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 86, 611\u2013614 (2008).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR62","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2893.2007.00907.x","volume":"15","author":"F Fabrizi","year":"2008","unstructured":"Fabrizi, F., Dixit, V., Messa, P. & Martin, P. Interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Viral Hepat. 15, 79\u201388 (2008).","journal-title":"J. Viral Hepat."},{"key":"BFnrneph201037_CR63","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/j.1572-0241.2003.07526.x","volume":"98","author":"MW Russo","year":"2003","unstructured":"Russo, M. W., Goldsweig, C. D., Jacobson, I. M. & Brown, R. S. Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am. J. Gastroenterol. 98, 1610\u20131615 (2003).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrneph201037_CR64","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1038\/ki.1995.198","volume":"47","author":"S Pol","year":"1995","unstructured":"Pol, S. et al. Efficacy and tolerance of alpha-2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int. 47, 1412\u20131418 (1995).","journal-title":"Kidney Int."},{"key":"BFnrneph201037_CR65","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000045971","volume":"88","author":"C Hanrotel","year":"2001","unstructured":"Hanrotel, C. et al. Virological and histological responses to one-year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 88, 120\u2013126 (2001).","journal-title":"Nephron"},{"key":"BFnrneph201037_CR66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1365-2893.1997.tb00213.x","volume":"4","author":"JL Fern\u00e1ndez","year":"1997","unstructured":"Fern\u00e1ndez, J. L., Rendo, P., del Pino, N. & Viola, L. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels. Nephrologists' Group for the Study of HCV Infection. J. Viral Hepat. 4, 113\u2013119 (1997).","journal-title":"J. Viral Hepat."},{"key":"BFnrneph201037_CR67","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1093\/ndt\/14.11.2704","volume":"14","author":"JM Campistol","year":"1999","unstructured":"Campistol, J. M. et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol. Dial. Transplant. 14, 2704\u20132709 (1999).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR68","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1159\/000046646","volume":"21","author":"S Huraib","year":"2001","unstructured":"Huraib, S., Iqbal, A., Tanimu, D. & Abdullah, A. Sustained virological and histological response with pretransplant interferon therapy in renal transplant patients with chronic hepatitis C. Am. J. Nephrol. 21, 435\u2013440 (2001).","journal-title":"Am. J. Nephrol."},{"key":"BFnrneph201037_CR69","doi-asserted-by":"publisher","first-page":"c133","DOI":"10.1159\/000085442","volume":"100","author":"IM Mahmoud","year":"2005","unstructured":"Mahmoud, I. M. et al. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin. Pract. 100, c133\u2013c139 (2005).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph201037_CR70","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1478-3231.2005.01225.x","volume":"26","author":"CM Rocha","year":"2006","unstructured":"Rocha, C. M. et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int. 26, 305\u2013310 (2006).","journal-title":"Liver Int."},{"key":"BFnrneph201037_CR71","first-page":"285","volume":"10","author":"I Sporea","year":"2001","unstructured":"Sporea, I. et al. Effect of alpha 2b interferon treatment in hemodialyzed patients with chronic hepatitis C. Rom. J. Gastroenterol. 10, 285\u2013288 (2001).","journal-title":"Rom. J. Gastroenterol."},{"key":"BFnrneph201037_CR72","doi-asserted-by":"publisher","first-page":"c8","DOI":"10.1159\/000090505","volume":"103","author":"I Grgurevic","year":"2006","unstructured":"Grgurevic, I. et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin. Pract. 103, c8\u2013c11 (2006).","journal-title":"Nephron Clin. Pract."},{"key":"BFnrneph201037_CR73","first-page":"1170","volume":"96","author":"T Casanovas-Taltavull","year":"2001","unstructured":"Casanovas-Taltavull, T. et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am. J. Gastroenterol. 96, 1170\u20131177 (2001).","journal-title":"Am. J. Gastroenterol."},{"key":"BFnrneph201037_CR74","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1093\/ndt\/16.5.1017","volume":"16","author":"F Degos","year":"2001","unstructured":"Degos, F. et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol. Dial. Transplant. 16, 1017\u20131023 (2001).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR75","unstructured":"Fabrizi, F., Dixit, V., Messa, P. & Martin, P. Pegylated interferon monotherapy of chronic hepatitis C in dialysis patients: meta-analysis of clinical trials. J. Med. Virol. (in press)."},{"key":"BFnrneph201037_CR76","first-page":"794","volume":"19","author":"A Covic","year":"2006","unstructured":"Covic, A. et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J. Nephrol. 19, 794\u2013801 (2006).","journal-title":"J. Nephrol."},{"key":"BFnrneph201037_CR77","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ndt\/gfi231","volume":"21","author":"MW Russo","year":"2006","unstructured":"Russo, M. W., Ghalib, R., Sigal, S. & Joshi, V. Randomized trial of pegylated interferon alpha-2b monotherapy in hemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 21, 437\u2013443 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR78","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.3748\/wjg.v12.i26.4191","volume":"12","author":"I Sporea","year":"2006","unstructured":"Sporea, I. et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic hemodialysis. World J. Gastroenterol. 12, 4191\u20134194 (2006).","journal-title":"World J. Gastroenterol."},{"key":"BFnrneph201037_CR79","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.transproceed.2007.07.013","volume":"39","author":"T Casanovas-Taltavull","year":"2007","unstructured":"Casanovas-Taltavull, T. et al. Preliminary results of treatment with pegylated interferon alpha2a for chronic hepatitis C virus in kidney transplant candidates on hemodialysis. Transplant. Proc. 39, 2125\u20132127 (2007).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR80","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1440-1797.2006.00662.x","volume":"12","author":"TM Chan","year":"2007","unstructured":"Chan, T. M. et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 12, 11\u201317 (2007).","journal-title":"Nephrology"},{"key":"BFnrneph201037_CR81","first-page":"16","volume":"28","author":"DN Amarapurkar","year":"2007","unstructured":"Amarapurkar, D. N., Patel, N. D. & Kirpalani, A. L. Monotherapy with peginterferon alpha-2b (12kDa) for chronic hepatitis C infection in patients undergoing haemodialysis. Trop. Gastroenterol. 28, 16\u201318 (2007).","journal-title":"Trop. Gastroenterol."},{"key":"BFnrneph201037_CR82","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5414\/CNP67366","volume":"6","author":"M Espinosa","year":"2007","unstructured":"Espinosa, M. et al. Anemia associated with pegylated interferon-alpha2a and alpha2b therapy in hemodialysis patients. Clin. Nephrol. 6, 366\u2013373 (2007).","journal-title":"Clin. Nephrol."},{"key":"BFnrneph201037_CR83","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1136\/gut.2007.133884","volume":"57","author":"CH Liu","year":"2008","unstructured":"Liu, C. H. et al. Pegylated interferon alpha-2a versus standard interferon alpha-2a for treatment-na\u00efve dialysis patients with chronic hepatitis C: a randomised study. Gut 57, 525\u2013530 (2008).","journal-title":"Gut"},{"key":"BFnrneph201037_CR84","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s15010-008-7134-z","volume":"36","author":"SC Akhan","year":"2008","unstructured":"Akhan, S. C., Kalender, B. & Ruzgar, M. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection. Infection 36, 341\u2013344 (2008).","journal-title":"Infection"},{"key":"BFnrneph201037_CR85","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3748\/wjg.14.255","volume":"14","author":"C Ayaz","year":"2008","unstructured":"Ayaz, C., Celen, M. K., Yuce, U. N. & Geyik, M. F. Efficacy and safety of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. World J. Gastroenterol. 14, 255\u2013259 (2008).","journal-title":"World J. Gastroenterol."},{"key":"BFnrneph201037_CR86","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2036.2004.01954.x","volume":"20","author":"BE Annicchiarico","year":"2004","unstructured":"Annicchiarico, B. E. & Siciliano, M. Pegylated interferon alpha-2b monotherapy for hemodialysis patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 20, 123\u2013124 (2004).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrneph201037_CR87","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1111\/j.1440-1746.2005.04008.x","volume":"21","author":"OF Kokoglu","year":"2006","unstructured":"Kokoglu, O. F. et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J. Gastroenterol. Hepatol. 21, 575\u2013580 (2006).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"BFnrneph201037_CR88","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/08860220701641579","volume":"29","author":"A Sikole","year":"2007","unstructured":"Sikole, A. et al. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a monotherapy. Ren. Fail. 29, 961\u2013966 (2007).","journal-title":"Ren. Fail."},{"key":"BFnrneph201037_CR89","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/ndt\/gfh747","volume":"20","author":"D Teta","year":"2005","unstructured":"Teta, D. et al. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol. Dial. Transplant. 20, 991\u2013993 (2005).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR90","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00535-009-0016-z","volume":"44","author":"S Kose","year":"2009","unstructured":"Kose, S., Gurkan, A., Akman, F., Kelesoglu, M. & Uner, U. Treatment of hepatitis C in hemodialysis patients using pegylated interferon alpha-2a in Turkey. J. Gastroenterol. 44, 353\u2013358 (2009).","journal-title":"J. Gastroenterol."},{"key":"BFnrneph201037_CR91","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1177\/039139880903200309","volume":"32","author":"P Dzekova","year":"2009","unstructured":"Dzekova, P. et al. Long-term follow up of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients. Int. J. Artif. Organs 32, 180\u2013184 (2009).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR92","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.transproceed.2004.07.025","volume":"36","author":"DH Mousa","year":"2004","unstructured":"Mousa, D. H. et al. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant. Proc. 36, 1831\u20131834 (2004).","journal-title":"Transplant. Proc."},{"key":"BFnrneph201037_CR93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1046\/j.1365-2893.2001.00300.x","volume":"8","author":"A Bruchfeld","year":"2001","unstructured":"Bruchfeld, A., St\u00e5hle, L., Andersson, J. & Schvarcz, R. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection\u2014a pilot study. J. Viral Hepat. 8, 287\u2013292 (2001).","journal-title":"J. Viral Hepat."},{"key":"BFnrneph201037_CR94","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ndt\/16.1.193","volume":"16","author":"AC Tan","year":"2001","unstructured":"Tan, A. C. et al. Safety of interferon and ribavirin therapy in hemodialysis patients with chronic hepatitis C: results of a pilot study [letter]. Nephrol. Dial. Transplant. 16, 193\u2013195 (2001).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR95","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","volume":"46","author":"M Rendina","year":"2007","unstructured":"Rendina, M. et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant. J. Hepatol. 46, 768\u2013774 (2007).","journal-title":"J. Hepatol."},{"key":"BFnrneph201037_CR96","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1093\/ndt\/gfl072","volume":"21","author":"A Bruchfeld","year":"2006","unstructured":"Bruchfeld, A., Lindahl, K., Reichard, O., Carlsson, T. & Schvarcz, R. Pegylated interferon and ribavirin in hemodialysis patients. Nephrol. Dial. Transplant. 21, 1444\u20131445 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR97","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1093\/ndt\/gfm724","volume":"23","author":"R Van Leusen","year":"2008","unstructured":"Van Leusen, R. et al. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol. Dial. Transplant. 23, 721\u2013725 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR98","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/039139880803100404","volume":"31","author":"D Carriero","year":"2008","unstructured":"Carriero, D. et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int. J. Artif. Organs 31, 295\u2013302 (2008).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201037_CR99","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1097\/MCG.0b013e318180803a","volume":"43","author":"W Hakim","year":"2009","unstructured":"Hakim, W. et al. HCV response in patients with end stage renal disease treated with combination pegylated interferon alpha-2a and ribavirin. J. Clin. Gastroenterol. 43, 477\u2013481 (2009).","journal-title":"J. Clin. Gastroenterol."},{"key":"BFnrneph201037_CR100","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/gut.2008.165076","volume":"58","author":"CH Liu","year":"2009","unstructured":"Liu, C. H. et al. Pegylated interferon alpha-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy. Gut 58, 314\u2013316 (2009).","journal-title":"Gut"},{"key":"BFnrneph201037_CR101","first-page":"22","volume":"12","author":"V Schmitz","year":"2007","unstructured":"Schmitz, V. et al. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann. Transplant. 12, 22\u201327 (2007).","journal-title":"Ann. Transplant."},{"key":"BFnrneph201037_CR102","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","volume":"24","author":"A Bruchfeld","year":"2002","unstructured":"Bruchfeld, A., Lindahl, K., Schvarz, R. & St\u00e5hle, L. Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Ther. Drug Monit. 24, 701\u2013708 (2002).","journal-title":"Ther. Drug Monit."},{"key":"BFnrneph201037_CR103","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1159\/000189444","volume":"74","author":"L Rostaing","year":"1996","unstructured":"Rostaing, L. et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 74, 512\u2013516 (1996).","journal-title":"Nephron"},{"key":"BFnrneph201037_CR104","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1034\/j.1600-6143.2003.30113.x","volume":"3","author":"S Baid","year":"2003","unstructured":"Baid, S. et al. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am. J. Transplant. 3, 74\u201378 (2003).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR105","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/j.1399-0012.2006.00534.x","volume":"20","author":"RK Sharma","year":"2006","unstructured":"Sharma, R. K. et al. Chronic hepatitis C virus infection in renal transplant: treatment and outcome. Clin. Transplant. 20, 677\u2013683 (2006).","journal-title":"Clin. Transplant."},{"key":"BFnrneph201037_CR106","first-page":"2104","volume":"10","author":"O Ozg\u00fcr","year":"1995","unstructured":"Ozg\u00fcr, O., Boyacioglu, S., Telatar, H. & Haberal, M. Recombinant alpha-interferon in renal allograft recipients with chronic hepatitis C. Nephrol. Dial. Transplant. 10, 2104\u20132106 (1995).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR107","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/00007890-199409150-00018","volume":"58","author":"E Thervet","year":"1994","unstructured":"Thervet, E. et al. Low-dose recombinant leucocyte interferon-alpha treatment of hepatitis C viral infection in renal transplant recipients. A pilot study. Transplantation 58, 625\u2013628 (1994).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR108","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/j.1600-6143.2006.01374.x","volume":"6","author":"SJ Carbognin","year":"2006","unstructured":"Carbognin, S. J. et al. Acute renal allograft rejection following pegylated IFN-alpha treatment for chronic HCV in a repeat allograft recipients on hemodialysis: a case report. Am. J. Transplant. 6, 1746\u20131751 (2006).","journal-title":"Am. J. Transplant."},{"key":"BFnrneph201037_CR109","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/ndt\/gfm678","volume":"23","author":"H W\u00e9clawiak","year":"2008","unstructured":"W\u00e9clawiak, H. et al. Alpha-interferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol. Dial. Transplant. 23, 1043\u20131047 (2008).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201037_CR110","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1432-2277.2008.00831.x","volume":"22","author":"GP Pageaux","year":"2009","unstructured":"Pageaux, G. P. et al. Pegylated interferon-alpha-based treatment for chronic hepatitis C in renal transplant recipients: an open pilot study. Transpl. Int. 22, 562\u2013567 (2009).","journal-title":"Transpl. Int."},{"key":"BFnrneph201037_CR111","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2008.06.002","volume":"49","author":"J Sperl","year":"2008","unstructured":"Sperl, J., Petrasek, J., Spicak, J. & Viklicky, O. Acute rejection of non-functional allograft in kidney transplant recipients with hepatitis C treated with peginterferon-alpha 2a. J. Hepatol. 49, 461\u2013462 (2008).","journal-title":"J. Hepatol."},{"key":"BFnrneph201037_CR112","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1097\/00007890-199811150-00023","volume":"66","author":"CM Toth","year":"1998","unstructured":"Toth, C. M. et al. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon alpha therapy. Transplantation 66, 1254\u20131258 (1998).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR113","first-page":"1371","volume":"80","author":"A Risser","year":"2009","unstructured":"Risser, A., Donovan, D., Heintzman, J. & Page, T. NSAID prescribing precautions. Am. Fam. Physician 80, 1371\u20131378 (2009).","journal-title":"Am. Fam. Physician"},{"key":"BFnrneph201037_CR114","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2165\/00003088-198207030-00003","volume":"7","author":"E Myhre","year":"1982","unstructured":"Myhre, E., Rugstad, H. E. & Hansen, T. Clinical pharmacokinetics of methyldopa. Clin. Pharmacokinet. 7, 221\u2013233 (1982).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrneph201037_CR115","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1097\/00007890-199606270-00019","volume":"61","author":"S Pol","year":"1996","unstructured":"Pol, S. et al. Azathioprine hepatitis in kidney transplant recipients. A predisposing role of chronic viral hepatitis. Transplantation 61, 1774\u20131776 (1996).","journal-title":"Transplantation"},{"key":"BFnrneph201037_CR116","first-page":"193","volume":"53","author":"J Karamehic","year":"1999","unstructured":"Karamehic, J. et al. Hepatotoxicity of cyclosporine in patients with kidney transplants [Croatian]. Med. Arh. 53, 193\u2013195 (1999).","journal-title":"Med. Arh."},{"key":"BFnrneph201037_CR117","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/lt.20183","volume":"10","author":"GW Neff","year":"2004","unstructured":"Neff, G. W. et al. Consumption of dietary supplements in a liver transplant population. Liver Transpl. 10, 881\u2013885 (2004).","journal-title":"Liver Transpl."},{"key":"BFnrneph201037_CR118","doi-asserted-by":"crossref","unstructured":"Fong, T. L. et al. Hepatotoxicity due to hydroxycut: a case series. Am. J. Gastroenterol. doi:10.1038\/ajg.2010.5.","DOI":"10.1038\/ajg.2010.5"}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.37","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2010.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T23:27:14Z","timestamp":1740007634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2010.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,13]]},"references-count":118,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["BFnrneph201037"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2010.37","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,13]]}}}